Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan
|
|
- Millicent Flowers
- 7 years ago
- Views:
Transcription
1 Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan The International Economic Forum of the Americas Serge Lapointe, Ph.D. Partner, Patent Agent June 14, 2012
2 Introduction Drug development is long and very complex Only 1 out of 10,000 molecules 1 billion $ 1 medicinal product 0 5 yrs 10 yrs 15 yrs 20 yrs 25 yrs 10 years of research Commercialization 2
3 Introduction Exclusivity drives the pharmaceutical industry Innovators vs. Generics With different laws, governments try to achieve a balance: Need for new drugs vs. medicines at low cost 3
4 Introduction Drug development is long and very complex Real period of patent exclusivity and possible return on investment 1 medicinal product 0 5 yrs 10 yrs 15 yrs 20 yrs 25 yrs 10 years of research Commercialization Patent Expiry 4
5 Introduction Patents are not always available or the best vehicle Alternative form of protection exists and are essential for the pharma industry: «data exclusivity» cannot apply to the regulatory authorities «marketing exclusivity» no authorization granted by the authorities Essential in the life-cycle management of pharmaceuticals 5
6 United States
7 UNITED STATES World s largest market for pharmaceuticals Largest number of drug-related exclusivities Exclusivities for Innovators (6) Exclusivity for Generic companies (1) Biosimilar Biological Products 7
8 UNITED STATES Exclusivities for Innovators 30-Month Stay Under the Hatch-Waxman Act Legal regime by which the U.S. Food and Drug Administration (FDA) may be prevented from issuing an Abbreviated New Drug Application (ANDA) to a generic company Brand companies must list their patent(s) in the Orange Book When filing their ANDA, generic companies must address the patent(s) listed in the Orange Book If statement that the patent is invalid or will not be infringed, FDA will have to wait for a 30-month period before approving the ANDA 8
9 UNITED STATES Exclusivities for Innovators New Chemical Entity Exclusivity Available for any new drug containing a new chemical entity (NCE) Five (5) years of data and marketing exclusivity No approval of Abbreviated New Drug Application (ANDA) Orphan Drug Exclusivity Awarded only to drugs intended for the treatment of «rare disease or condition» Affecting less than 200,000 individuals in the U.S. No reasonable expectation of recovering development costs Seven (7) years of marketing exclusivity FDA is prevented from approving the same active drug for the same indication 9
10 UNITED STATES Exclusivities for Innovators New Use or New Formulation Exclusivity (New Clinical Study Exclusivity) Awarded only to drugs products that depend on new clinical investigation to support new therapeutic claims New formulations New indications of existing drug Three (3) years of marketing exclusivity FDA is prevented to approve an ANDA Pediatric Exclusivity Adds a six-month of marketing exclusivity to ANY existing exclusivity General exclusivity extension added to the end of any non-patent exclusivity Adds to the life of patented drug products listed in the Orange Book 10
11 UNITED STATES Exclusivities for Innovators Patent Term Extension or Patent Term Restoration Up to five (5) years to compensate for the delay before approval of the drug Limitations: The extension requires a valid and unexpired patent Only one patent may be extended per approved drug Extension period calculated on a day-by-day basis and is based on time spent in trials and time spent by FDA review Maximum of 14 years of patent term from the date of approval of the drug Advisable for the patentee to expedite issuance of the patent in order to maximize its extension 11
12 UNITED STATES Exclusivities for Generic Companies 180-Day Generic Product Exclusivity Aims to remove weak or non-infringed patents Available to the first generic company who successfully challenges the enforceability of a patent listed in the Orange Book Race to the market: 180-day period starts when the drug is first commercialized During the exclusivity period no other generic version of the same drug can be marketed Single most important motivator for the generic industry to challenge pharmaceutical patents 12
13 UNITED STATES Biosimilar Biological Products Top 10 Drug Products by Sales in 2014 Rank Product Company Technology WW Sales (m$) 1 Avastin Roche Monoclonal antibody 9,232 2 Humira Abbott & Eisai Monoclonal antibody 9,134 3 Rituxan Roche Monoclonal antibody 7,815 4 Enbrel Wyeth, Amgen & Takeda Recombinant product 6,583 5 Lantus Sanofi-Aventis Recombinant product 6,386 6 Herceptin Roche Monoclonal antibody 5,796 7 Crestor AstraZeneca Small molecule chemistry 5,739 8 Spiriva Boehringer Ingelheim Small molecule chemistry 5,552 9 Remicade SGP, J&J et Mitsubishi Tanabe Monoclonal antibody 5, Gleevec/Glivec Novartis Small molecule chemistry 5,136 13
14 UNITED STATES Biosimilar Biological Products New legislation enacted in 2010 to encourage innovation and promote competition for biological products Highly complex and many ramifications Two pathways: Biosimilars and Interchangables FDA regulatory approval requirements Newly available exclusivities Innovators: Up to 12 years of exclusive use of a reference biological products before biosimilars can be approved for marketing Generics: Exclusivity for the first product determined to be interchangeable with a pioneer reference biologic Can range from one (1) year after the first commercialization Up to forty-two (42) months after approval 14
15 Canada
16 CANADA Pharmaceutical sector is one of the most innovative and profitable industries 3% share of the global market 9 th largest world market Shared by brand-name and generic drug companies More than 390 pharmaceuticals More than 400 biotechs Mechanisms of protection much less extensive than the U.S. 16
17 CANADA Patented Medicine (NOC) Regulations Many similarities with the 30-month stay in the U.S. Brand companies must list their patents for an approved drug on the Patent register When filing an abbreviated new drug submission (ANDS) the generic companies must address the patents listed on the Patent register If the generic challenges the validity or infringement of the patent, the innovator may apply to the court for an order prohibiting the minister (Health Canada) Minister can not issue a NOC to the generic for a period of up to 24 months 17
18 CANADA Innovative Drugs Eight-year exclusivity protection for innovative drugs approved after June 17, 2006 a drug that contains a medicinal ingredient not previously approved in a drug by the Minister is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph Six (6) years of data exclusivity, plus Two (2) years of marketing exclusivity May subjected to further six-month extension for pediatric studies 18
19 CANADA Patent Term Restoration 20 years of patent protection under the Canadian Patent Act Unlike most industrial countries, NO patent term restoration or patent term extension in Canada 19
20 CANADA Subsequent-Entry Biologics Subsequent-Entry Biologics (SEBs) correspond to U.S. biosimilars Defined as a biologic product that is similar to and would enter the market subsequent to an approved innovator biologic product NO Exclusivity: SEBs are not considered to be innovative drug and cannot qualify for data protection SEBs are subject to regulatory restrictions about data protection awarded to another innovative product SEBs are subject to the NOC Regulations 20
21 Europe
22 EUROPE New Chemical Entity Most generous system for drugs submitted for authorization on or after November 1, 2005 Up to 11 years of exclusivity for a new chemical entity (NCE) Harmonized formula: 8 years of data exclusivity for an NCE Additional 2 years of marketing exclusivity and 1 additional year of marketing exclusivity if the new product is for treating a significant new indication 22
23 EUROPE Orphan Drugs and Pediatric Exclusivity Orphan drugs Disease affects no more than 5 people out of 10,000 in the European Union 10 years of marketing exclusivity from the date of approval An additional 2 years of market exclusivity can be granted to pediatric orphan drugs (i.e. total of 12 years) Pediatric Exclusivity Available for patented pediatric drugs Additional six-month extension to existing patent term extensions (SPCs) 23
24 EUROPE Patent Term Extension Patent term extensions may be obtained for pharmaceutical products through a Supplementary Protection Certificate (SPCs) Duration: Time lost between the filing date of the patent application and the date of first regulatory approval, minus 5 years Maximum term of SPC is 5 years 24
25 Japan
26 JAPAN The second-largest pharmaceutical market in the world Different legal mechanisms of exclusivity for innovators Up to 8 years of protection for NCEs (data exclusivity) 4-6 years of data exclusivity for certain improvements 10 years of data exclusivity for orphan drugs Up to 5 years of patent term extension 26
27 Summary of Non-patent Exclusivity or Patent Term Extension for Drugs Duration Type of Exclusivity or Extension U.S. Europe Japan Canada Delay by health authority approval 30 mths X X 24 mths New Chemical Entity (NCE) 5 yrs yrs 8 yrs 8 yrs Orphan Drug 7 yrs yrs 10 yrs X Pediatric 6 mths 6 mths 2 yrs 6 mths New Use or New formulation 3 yrs X 4/6 yrs X Patent Term Extension Max. 5 yrs Max. 5 yrs Max. 5 yrs X Biosimilars Max. 12 yrs same as NCE same as NCE X 27
28 Conclusions Pharma business model is challenged Increasing cost for R&D Longer clinical trials Lesser approval Patent expiration and litigation Sufficient time to recoup investment? How to attract companies and investors? 28
29 Conclusions Need for greater intellectual property protection in Canada Deficiencies in data protection and marketing exclusivities Only G8 country with no patent term extensions Shortcomings to be corrected as part of the ongoing negotiations of a free-trade agreement between Canada and the European Union? 29
30 Thank you! Serge Lapointe, Ph.D. Partner, Patent Agent DM
Pharmaceutical development is an expensive, time
Exclusivity Strategies in the United States and European Union by Carolyne Hathaway, John Manthei and Cassie Scherer Pharmaceutical development is an expensive, time consuming and uncertain process that
More informationA Comparison of US and EU Biosimilars Regimes
A Comparison of US and EU Biosimilars Regimes summary statement Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different
More informationThe 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
More informationPATENTS. Pharmaceutical Product Patenting Strategies
PATENTS Pharmaceutical Product Patenting Strategies 1. What is a product patent? A product patent is a patent giving protection to a product as such, e.g. as an apparatus, a device or a chemical compound.
More informationBiologics: Specific Drug Safety Challenges. Violetta B. Kyburz
Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics
More informationPharmaceutical royalties: a new securitisation frontier Malcolm S Dorris Dechert LLP. Dechert LLP 2007
10 Pharmaceutical royalties: a new securitisation frontier Malcolm S Dorris 2007 Securitisation techniques have been increasingly used in less traditional financings involving a wide variety of asset classes.
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationGuidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationYou Know It Is Coming: Preparing for the Paragraph IV Letter
You Know It Is Coming: Preparing for the Paragraph IV Letter John Farrell, Fish & Richardson Matt Onaitis, Somaxon William Scarff, Allergan Jonathan Singer, Fish & Richardson Table of Contents Regulatory
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More informationGlobal Pharmaceutical Trade and Contribution of India
Global Pharmaceutical Trade and Contribution of India TPR Rau. B. S 1 and Dr. Appaji P. V 2 Abstract: Trends in global pharmaceutical market in terms of sale, product category, product, regions and countries
More informationSUPPLEMENTARY PROTECTION CERTIFICATES FOR MEDICINAL PRODUCTS
SUPPLEMENTARY PROTECTION CERTIFICATES FOR MEDICINAL PRODUCTS A Supplementary Protection Certificate (SPC) is an Intellectual Property right which can give up to five extra years of exclusivity after a
More informationAdopt IP Protections to Ensure Regulatory Exclusivity for Orphan Drugs
30-Second Summary Orphan drugs present unique risks the potential return on investment is inherently constrained by small patient populations and attendant reimbursement challenges. Recognizing these challenges,
More informationThe Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts
More informationCompany Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More informationFDLI s IP Throughout the Drug Development Lifecycle
FDLI s IP Throughout the Drug Development Lifecycle Post-Marketing IP Protection & Enforcement: View From the Generic Side Janine A. Carlan Arent Fox LLP Topics To Be Discussed Hatch-Waxman Process Orange
More informationCommercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationCanada s Patented Medicines (Notice of Compliance) Regulations: Removing Inefficiencies to Encourage Generic Competition
Canada s Patented Medicines (Notice of Compliance) Regulations: Removing Inefficiencies to Encourage Generic Competition by Suzanne Marie Porter A thesis submitted in conformity with the requirements for
More informationHybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs
Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Drug Information Journal 00(0) 1-6 ª The Author(s) 2012
More informationHOT TOPICS IN IN HEALTH CARE REFORM
By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable
More informationTABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.
1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed
More informationMonoclonal antibody (mab) products are currently a fast
Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,
More informationEconomical Approaches to Meeting Global Demand for High Value Biopharmaceuticals
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants
More informationEC s Preliminary Pharmaceutical Sector Report: An Aggressive Review of Industry Conduct
FEBRUARY 2009, RELEASE TWO EC s Preliminary Pharmaceutical Sector Report: An Aggressive Review of Industry Conduct Susan A. Creighton & Seth C. Silber Wilson, Sonsini, Goodrich and Rosati EC s Preliminary
More informationKey Findings. Use this report to... The Autoimmune Market Outlook to 2013
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
More informationPHARMACEUTICAL INDUSTRY PROFILE
PHARMACEUTICAL INDUSTRY PROFILE I. INDUSTRY BACKGROUND A. Industry Definition The U.S. pharmaceutical industry is defined by the Census Bureau as companies engaged in researching, developing, manufacturing,
More informationApplication of Patent Litigation Strategies to Biosimilars: Is there a difference?
Application of Patent Litigation Strategies to Biosimilars: Is there a difference? Kristof Roox, Partner Crowell & Moring Brussels (kroox@crowell.com) November 19, 2009 Berlin, Germany I. Overview of strategies
More informationDrug Re-Examination/Data Exclusivity in JAPAN and Neighboring Countries
Japan Pharmaceutical Manufacturers & Association Drug Re-Examination/Data Exclusivity in JAPAN and Neighboring Countries AIPPI Forum & ExCo Workshop Pharma IV September 6, 2013 at Helsinki Yoichi OKUMURA
More informationGuidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day
Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
More informationAnnual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
More informationPharmaceutical industry
8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and
More informationFirst to File and Beyond: Paragraph IV Business Strategies
First to File and Beyond: Paragraph IV Business Strategies THOMSON REUTERS INTELLECTUAL PROPERTY & SCIENCE GENERICS & API INTELLIGENCE Benjamin Burck Research Analyst and Project Manager Generics & API
More informationPharma Lifecycle Management and Brand Defense Strategy. Strategic and Tactical Options for Continuing Your Product Success Story
Pharma Lifecycle Management and Brand Defense Strategy Strategic and Tactical Options for Continuing Your Product Success Story Pharma Lifecycle Management and Brand Defense Strategy 20 July 2014 Terminology
More informationIMPACT OF PATENT SETTLEMENTS ON DRUG COSTS: ESTIMATION OF SAVINGS
Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. IMPACT OF
More informationRachel Kreppel CLINICAL TRIALS: A NEW FORM OF INTELLECTUAL PROPERTY? Introduction
Rachel Kreppel CLINICAL TRIALS: A NEW FORM OF INTELLECTUAL PROPERTY? Introduction Clinical trials are not adequately protected by current forms of intellectual property and should be recognized as a new
More informationImplementation of Advanced Chromatography techniques to Mitigate Purification Concerns in Bispecific Monoclonal Antibody Manufacturing
www.beroe- WHITEPAPER December 2012 inc.com Implementation of Advanced Chromatography techniques to Multi Column Solvent Gradient Purification or MCSGP chromatography process is a better solution to Bispecific
More informationBiosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies
Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is
More informationPharmaceutical royalties: a new securitisation frontier
Pharmaceutical royalties: a new securitisation frontier Dechert LLP This article first appeared in Global Securitisation and Structured Finance 2004, published by Globe White Page Ltd, www.globalsecuritisation.com.
More informationSmall Business Assistance
Small Business Assistance Products Ronald.Wilson@fda.hhs.gov Financial Assistance and Incentives for Research and Development of New Drug/Biologic Ron Wilson, Director of Small Business Assistance Center
More information(SAMPLE COPY, NOT FOR RESALE)
TriMark Publications June 2009 Volume: TMRTMA09-0601 THERAPEUTIC MONOCLONAL ANTIBODIES MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF
More informationFrom I.P to N.P A Call for a New Paradigm. Dr A. Schwartz
From I.P to N.P A Call for a New Paradigm Dr A. Schwartz The Innovative Pharmaceutical business model Big Pharma identifies unmet clinical need Innovator loses Revenue on Older Products, Necessitating
More informationOvercoming Restriction Requirements On Pharma Patents
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Overcoming Restriction Requirements On Pharma Patents
More informationGlobal Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)
Brochure More information from http://www.researchandmarkets.com/reports/2693611/ Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018) Description: The report titled 'Global Rheumatoid
More informationNew Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationItaly. Roundtable on: Role of Competition in the Pharmaceutical Sector and its Benefits for Consumers
Seventh United Nations Conference to review the UN Set on Competition Policy Geneva, 6-10 July 2015 Roundtable on: Role of Competition in the Pharmaceutical Sector and its Benefits for Consumers Statement
More informationGlobal Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationBiologics Biosimilars
Biologics Biosimilars Q u e st i o n s Po l i c y S a fe t y What are biosimilars? Biosimilars are sometimes incorrectly and inappropriately called generic versions of original biological medicines. But
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationCommercial Insight Osteoarthritis and Rheumatoid Arthritis
A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and
More informationPay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions. An FTC Staff Study January 2010. Federal Trade Commission ftc.
Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions An FTC Staff Study January 2010 Federal Trade Commission ftc.gov Summary Brand-name pharmaceutical companies can delay generic competition
More informationSubtitle I Sense of the Senate Regarding Medical Malpractice
H. R. 3590 686 (3) TITLE XI. Title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is amended (A) in section 1128(h)(3) (i) by inserting subtitle 1 of before title XX ; and (ii) by striking such
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationWarren D.Woessner 612-373-6903 wwoessner@slwk.com. William F. Prout 612-373-6968 wprout@slwk.com
Warren D.Woessner 612-373-6903 wwoessner@slwk.com William F. Prout 612-373-6968 wprout@slwk.com Schwegman Lundberg Woessner & Kluth 121 S. 8 th Street (1600) Minneapolis, MN 55419 612-373-6900 1 William
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationPEDIATRIC MEDICINES: GLOBAL MARKETS
PEDIATRIC MEDICINES: GLOBAL MARKETS PHM170A October 2014 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-56965-971-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationNovember 4, 2010. Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington, DC 20515.
CONGRESSIONAL BUDGET OFFICE U.S. Congress Washington, DC 20515 Douglas W. Elmendorf, Director November 4, 2010 Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington,
More informationStakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationFDA USER FEES 2012: HOW INNOVATION HELPS PATIENTS
SUMMARY OF THE GENERIC PHARMACEUTICAL ASSOCIATION TESTIMONY BEFORE THE ENERGY AND COMMERCE SUBCOMMITTEE ON HEALTH UNITED STATES HOUSE OF REPRESENTATIVES APRIL 18, 2012 FDA USER FEES 2012: HOW INNOVATION
More informationWHITE PAPER. Developing Biosimilars in Emerging Markets: Regulatory and Clinical Considerations
WHITE PAPER Developing Biosimilars in Emerging Markets: Regulatory and Clinical Considerations ppdi.com March 2013 EXECUTIVE SUMMARY Emerging markets in Asia Pacific, Latin America and Eastern Europe are
More informationWinter 2013. Changing landscapes, pipeline products and plan sponsor impact
Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationThe Basics of Pharmacy Benefits Management (PBM) 2009
The Basics of Pharmacy Benefits Management (PBM) 2009 Andrew Kingery Pharmacy Account Management Virginia CE Forum 2009 Course# 201719 Objectives & Introduction Provide basic components of a PBM Define
More informationOncoxx Biotech. Saverio Alberti. Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis
Oncoxx Biotech Saverio Alberti Anti-Trop-2 monoclonal antibodies for cancer therapy and target diagnosis INTRODUCTION Oncoxx S.r.l. is a Cancer Biotech Company as partnership between Chieti University
More informationOMT, Inc. Acquisition Conference Call December 17, 2015 NASDAQ: LGND
OMT, Inc. Acquisition Conference Call December 17, 2015 NASDAQ: LGND Safe Harbor Statement The following presentation contains forward-looking statements regarding Ligand s prospects, plans and strategies,
More informationAppendix A 2014 Financial Report
Appendix A 2014 Financial Report Financial Review INTRODUCTION Our Financial Review is provided to assist readers in understanding the results of operations, financial condition and cash flows of Pfizer
More informationIntroduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs
Introduction to Drug Naming Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs What s in a Name? International Nonproprietary Names (INN) Sponsored by World Health
More informationAccelerating Drug & Clinical Trial Approvals in China & East Asia
25 28 March 2014 The Westin Beijing Chaoyang, Accelerating Drug & Clinical Trial Approvals in & East Asia What s New in 2014? Key Regulatory Update from the National Institute for Food & Drug Control,
More informationPatent Expiry Impact Predictor
Patent Expiry Impact Predictor Compiled and written by Datamonitor plc Datamonitor plc (DTML) is a premium business information company specialising in industry analysis and providing clients with unbiased
More informationDOUBLE PATENTING CONSIDERATIONS by Mark Cohen
DOUBLE PATENTING CONSIDERATIONS by Mark Cohen The Federal Circuit recently issued an important decision with respect to restriction practice and obviousness double patenting in Pfizer Inc. v. Teva Pharmaceuticals
More informationManufacturer of drug substance
Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin
More informationLife Sciences & Healthcare
Life Sciences & Healthcare 03 Taylor Wessing is a leading European law firm advising life sciences and healthcare businesses, those who fund them and those who work for them Taylor Wessing has been voted:
More informationScott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry
Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationFDA Regulation of Follow-On Biologics
Judith A. Johnson Specialist in Biomedical Policy April 26, 2010 Congressional Research Service CRS Report for Congress Prepared for Members and Committees of Congress 7-5700 www.crs.gov RL34045 c11173008
More informationBrand Quality with Asian Advantages
Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com
More informationPutting patients at the center of a new biopharma business model
23 of a new biopharma business model Edouard Croufer, Françoise Simon, François Meurgey and Alexandre Meire The pharmaceutical industry is suffering. Expiring patents, increasing demands from regulators
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationPaul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS
Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions
More informationImplication of China 2012 NEDL. Presented by: Li Xingwei Yong Hueyling
Implication of China 2012 NEDL to MNC pharma players Presented by: Li Xingwei Yong Hueyling Content Brief introduction of China NEDL policy China hospital system & MNCs Business Focus Influence of 2012
More informationGoals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
More informationBiopharmaceuticals and Products Liability Litigation
Biopharmaceuticals and Products Liability Litigation Steven Weisman, Ph.D. Head, Global Healthcare Products Innovative Science Solutions ABA Roundtable April 17, 2013 Krista L. Cosner Counsel Drinker Biddle
More informationGM: Thank you, Husein.
HUSEIN PANJU:. On today s show, I m very happy to welcome my guest Geoff Mowatt. Geoff is a partner with Dimock Stratton LLP in Toronto and is a certified specialist in patent law. His practice includes
More informationBiomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationGlobal Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
More informationRx-360 An International Pharmaceutical Supply Chain Consortium
Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)
More informationImpact of Health Reform on Prescription Drugs
Impact of Health Reform on Prescription Drugs 1 Indirect Effects Increased Rx Volume = More Prescriptions! Page 2 Retiree Drug Subsidy (RDS) Before HCR Tax-Free Subsidy RDS as taxdeductible income After
More informationMultiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth
Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine
More informationHow To Teach A Patent Course On Life Sciences
Patent Course offered by Highlights 2012 Patents in Life Sciences: An Update Madrid, 27 February 2012 Barcelona, 28 February 2012 Introduction Under the term "Patent Highlights" the organizers want to
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
More informationRegulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG
Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory
More informationBreast Cancer Drug Discoveries: What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to
More informationCase 1:15-cv-01120-UNA Document 1 Filed 12/03/15 Page 1 of 49 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:15-cv-01120-UNA Document 1 Filed 12/03/15 Page 1 of 49 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE UNIMED PHARMACEUTICALS, LLC, BESINS HEALTHCARE INC., and BESINS
More informationThe Benefits of Patent Settlements: New Survey Evidence on Factors Affecting Generic Drug Investment
The Benefits of Patent Settlements: New Survey Evidence on Factors Affecting Generic Drug Investment by Bret Dickey 1 Jonathan Orszag 2 July 23, 2013 3 1 Bret Dickey is an Executive Vice President with
More information1) SCOPE OF THE PROGRAM
CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany
More informationFDA Center for Drug Evaluation and Research (CDER)
FDA Center for Drug Evaluation and Research (CDER) Strategic Plan 2013-2017 Table of Contents Section Page I. Introduction.. 3 II. CDER Mission and Basic Business Model.. 3 III. Stakeholder Considerations
More informationEmerging Health Care Issues: Follow-on Biologic Drug Competition. Federal Trade Commission Report June 2009
Emerging Health Care Issues: Follow-on Biologic Drug Competition Federal Trade Commission Report June 2009 FEDERAL TRADE COMMISSION JON LEIBOWITZ Chairman PAMELA JONES HARBOUR Commissioner WILLIAM E. KOVACIC
More informationOFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013
Introduction OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 In 2007, Attorney General Wasden filed lawsuits against 33 pharmaceutical companies for
More information